Abstract 306P
Background
Optimal adjuvant treatment for stage IA uterine papillary serous (UPSC) or clear cell carcinomas (UCCC) remains unknown. Options include no adjuvant treatment or systemic chemotherapy, Pelvic RT and Vaginal brachytherapy alone or in combination. These subtypes represent an infrequent set of patients, and hence there is lack of randomized trial data to guide optimal management. The aim of this study was to evaluate treatment patterns and relapse characteristics in this uncommon subtype based on the retrospective data from a single centre.
Methods
Clinicopathologic data, treatment patterns and relapse characteristics were retrospectively collected on patients of UPSC and UCCC treated between January 2014 and December 2018. Adjuvant treatment modalities used and their impact on relapse rates was analysed.
Results
We identified 21 patients who had undergone hysterectomy with bilateral salpingo-oophorectomy and were found to have stage 1A papillary serous or clear cell endometrial carcinoma. Nearly all patients (n-18, 85%) also underwent extended lymph node dissection of pelvic and para-aortic lymph nodes.
Median age at diagnosis was 61 years. Eighteen patients had uterine papillary serous carcinoma and three patients had clear cell histology. Eleven patients (52%) received systemic chemotherapy (six cycles of Paclitaxel and Carboplatin) with RT. and two patients received EBRT with or without VBT. Eight patients had no adjuvant treatment. At a median follow-up thirty months (range 6-63 months), six patient had experienced recurrences (28%). Nearly all the recurrences (n = 4) were in patients who received no adjuvant therapy with a relapse rate of 50% (4/8) in this subset. Four recurrences were distant metastasis while two were loco regional. At the time of last follow up, three patients with relapse had succumbed to their disease.
Conclusions
UPSC and UCCC are a distinct subtype of endometrial cancer and associated with an aggressive phenotype and high relapse rate even in patients with early stage. Systemic chemotherapy and Pelvic RT alone or in combination should always be considered in this group.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
227P - Proteomic analysis of urothelial lesions reveals novel diagnostic biomarkers to distinguish pathologic pitfalls and protein-protein interactions
Presenter: Changlim Hyun
Session: Poster Display
Resources:
Abstract
228P - Real-world data on dose adjustment of cabozantinib in advanced renal cell carcinoma
Presenter: Hemavathi Baskarane
Session: Poster Display
Resources:
Abstract
229P - The application of diffusion kurtosis imaging in predicting muscle invasion of bladder cancer: A comparison with conventional DWI
Presenter: Shuai Jiang
Session: Poster Display
Resources:
Abstract
230P - Oncological outcomes between partial cystectomy and radical cystectomy in solitary muscle invasive bladder cancer with downgraded T stage
Presenter: Ming Wei Hsu
Session: Poster Display
Resources:
Abstract
231P - BMI-predicted progression-free survival after pembrolizumab therapy for urothelial cancer: Asian version of BMI classification is suitable for Asian patients
Presenter: mirii harada
Session: Poster Display
Resources:
Abstract
232P - The immunosuppressive features of the 20S Proteasome β-subunit gene family in von Hippel-Lindau (VHL)-mutated clear cell renal cell carcinoma (ccRCC): A TCGA-based bioinformatics study
Presenter: Saja Alzghoul
Session: Poster Display
Resources:
Abstract
233P - The crosstalk between PBRM1 loss and tumor immune microenvironment (TIME) of clear cell renal cell carcinoma (ccRCC): A possible interconnection to immunotherapy response
Presenter: Ahmed Al Sharie
Session: Poster Display
Resources:
Abstract
235P - Do FGFR2 and 3 proteins have a role in the prognosis of urothelial bladder carcinoma?
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
236P - The effects of chemotherapy on body composition in patients with advanced urothelial carcinoma
Presenter: KOSUKE KITAMURA
Session: Poster Display
Resources:
Abstract
237P - Real-world analysis of adjuvant nivolumab in resected urothelial cancer: A single institute study in Taiwanese patients
Presenter: Mu-Hsin Chang
Session: Poster Display
Resources:
Abstract